Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Enovis to $62 from $70 and keeps an Outperform rating on the shares in an earnings preview for the MedTech, Life Science Tools and Diagnostics group.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENOV: